Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy

Executive Summary

The German pharma agreed to pay up to €210m to investigate ViraTherapeutics' lead candidate, VSV-GP, alone and in combination, with an option to buy ViraTherapeutics depending on the outcome of Phase I studies.

Advertisement

Related Content

Boehringer's Expanded Venture Fund: Innovation First, Returns Second
Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis
Start-Up Quarterly Statistics, Q3 2016
Boehringer Ingelheim Bullish In Oncology Despite Olmutinib U-Turn
Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration
Boehringer Increasingly Looking Outside For Oncology Growth
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097386

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel